Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), ranging from ...

The FDA has approved bevacizumab-nwgd, a biosimilar to bevacizumab, for intravenous use across multiple cancer types.

The global Cancer Immunotherapy Market is valued at USD 121.4 Billion in 2024 and is projected to reach a value of USD 294.4 ...

Bispecific antibodies (bsAbs) have emerged as a novel class of therapeutics, offering a dual-targeting strategy to enhance the therapeutic efficacy of monoclonal antibodies ... approaches are ...

The global cancer monoclonal antibodies (mAbs) market has witnessed remarkable growth, driven by advances in biotechnology, rising cancer prevalence, and the increasing demand for targeted therapies.

An In-depth Market Research ReportThe Cancer Biologics Market is one of the fastest-growing segments within the global ...

In 2023, bevacizumab sales in the U.S. were around $2.0 billion. Biocon Biologics serves over 5 million patients each year ...

Biocon Biologics, the biosimilar arm of Biocon has expanded its oncology portfolio with the USFDA approval of Jobevne, a ...

A super-resolution microscopy technique offers an unparalleled glimpse into how monoclonal antibodies bind to their targets ...

Cancer treatments like chemotherapy can lead to extensive hair loss. While hair may start regrowing 4 to 6 weeks after the ...

Synthetic antibodies have become the cornerstone of cancer therapies. This approach was also favored in the initial fight against COVID-19. However, their laboratory production is time-consuming ...